Aeterna Zentaris is in the biotechnology industry and is part of the healthcare sector. The company CEO is Michael Ward. AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing novel treatments in oncology, endocrinology and women’s health.



Previous Intraday Performance:

The AEZS shares had a previous change of -1.57% which opened at 3.21 and closed at 3.14. It moved to an intraday high of 3.24 and a low of 3.10.

SeekingAlpha:  Aeterna Zentaris misses by $0.34, misses on revenue

Historical Performance:

Over the last five trading days, AEZS shares returned -1.26% and in the past 30 trading days it returned -32.18%. Over three months, it changed -22.47%. In one year it has changed 59.39% and within that year its 52 week high was 5.57 and its 52 week low was 1.29. AEZS stock is 143.41% above its 52 week low.

Our calculations result in a 200 day moving average of 3.04 and a 50 day moving average of 4.05. Right now, AEZS stock is trading 3.28% above its 200 day moving average and may be a good opportunity to buy.

SeekingAlpha:  Aeterna Zentaris misses by $0.34, misses on revenue

Liquidity:

The company has a market cap of $50.9m with 16.2m shares outstanding and a float of 16.2m shares. Trading volume was 59,489 shares and has experienced an average volume of 180,858 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

Based on 1 analyst estimate, the estimated EPS for the next quarter is 0.04. The trailing twelve month EPS reported is 0.25 (trailing twelve month diluted EPS is -0.93), which comes to a trailing twelve month PE of 12.56.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019 -0.30
4thQtr 2018 -0.32
3rdQtr 2018 -0.15
2ndQtr 2018 -0.16
1stQtr 2018 0.87

EPS growth is an important number as it indicates the future prospects of Aeterna Zentaris; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -91.40% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 14.40% of institutional ownership.



The beta was calculated to be 1.29.

SeekingAlpha:  ADDvantage Technologies reports Q2 results

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -398.81%, return on assets is -52.59%, price-to-sales is 11.10 and price-to-book is 32.70.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 1  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 0  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here